Form 4 for CTSO Cytosorbents Corp
Accepted 2023-12-15 00:00:00 ET · period of report 2023-12-13 · accession 0001104659-23-126432 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-15 | 2023-12-13 | CTSO | Sobel Alan D. | Dir | P - Purchase | $1.33 | +22.6K | 101.9K | +28% | +$30.0K |
| D | 2023-12-15 | 2023-12-13 | CTSO | Sobel Alan D. | Dir | P - Purchase | — | +7,894 | 7,894 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-13 | P | A | 22,557 | $1.33 | 101,857 | D | — | — | (F1) These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. (F2) Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 32,557 shares of Common Stock owned directly by the reporting person. |
| 2 | Derivative | Common Stock Warrant (Right to Buy) | 2023-12-13 | P | A | 7,894 | — | 7,894 | D | $2.00 · 2023-12-13 to 2028-12-13 | 7,894 Common Stock | (F1) These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant. |